Martínez-Cáceres, E. M.

Link to this page

Authority KeyName Variants
707c6039-d812-45aa-ac23-c1a8ef98166f
  • Martínez-Cáceres, E. M. (1)
Projects

Author's Bibliography

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

Mansilla, M. J.; Presas-Rodríguez, S.; Teniente-Serra, A.; González-Larreategui, I.; Quirant-Sánchez, B.; Fondelli, F.; Nikolovski, Neda; Iwaszkiewicz-Grześ, D.; Chwojnicki, K.; Miljković, Đorđe; Trzonkowski, P.; Ramo-Tello, C.; Martínez-Cáceres, E. M.

(Springer Nature, 2021)

TY  - JOUR
AU  - Mansilla, M. J.
AU  - Presas-Rodríguez, S.
AU  - Teniente-Serra, A.
AU  - González-Larreategui, I.
AU  - Quirant-Sánchez, B.
AU  - Fondelli, F.
AU  - Nikolovski, Neda
AU  - Iwaszkiewicz-Grześ, D.
AU  - Chwojnicki, K.
AU  - Miljković, Đorđe
AU  - Trzonkowski, P.
AU  - Ramo-Tello, C.
AU  - Martínez-Cáceres, E. M.
PY  - 2021
UR  - https://doi.org/10.1038/s41423-020-00618-z
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4235
AB  - Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.
PB  - Springer Nature
T2  - Cellular and Molecular Immunology
T1  - Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
IS  - 6
VL  - 18
DO  - 10.1038/s41423-020-00618-z
SP  - 1353
EP  - 1374
ER  - 
@article{
author = "Mansilla, M. J. and Presas-Rodríguez, S. and Teniente-Serra, A. and González-Larreategui, I. and Quirant-Sánchez, B. and Fondelli, F. and Nikolovski, Neda and Iwaszkiewicz-Grześ, D. and Chwojnicki, K. and Miljković, Đorđe and Trzonkowski, P. and Ramo-Tello, C. and Martínez-Cáceres, E. M.",
year = "2021",
abstract = "Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.",
publisher = "Springer Nature",
journal = "Cellular and Molecular Immunology",
title = "Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy",
number = "6",
volume = "18",
doi = "10.1038/s41423-020-00618-z",
pages = "1353-1374"
}
Mansilla, M. J., Presas-Rodríguez, S., Teniente-Serra, A., González-Larreategui, I., Quirant-Sánchez, B., Fondelli, F., Nikolovski, N., Iwaszkiewicz-Grześ, D., Chwojnicki, K., Miljković, Đ., Trzonkowski, P., Ramo-Tello, C.,& Martínez-Cáceres, E. M.. (2021). Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. in Cellular and Molecular Immunology
Springer Nature., 18(6), 1353-1374.
https://doi.org/10.1038/s41423-020-00618-z
Mansilla MJ, Presas-Rodríguez S, Teniente-Serra A, González-Larreategui I, Quirant-Sánchez B, Fondelli F, Nikolovski N, Iwaszkiewicz-Grześ D, Chwojnicki K, Miljković Đ, Trzonkowski P, Ramo-Tello C, Martínez-Cáceres EM. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. in Cellular and Molecular Immunology. 2021;18(6):1353-1374.
doi:10.1038/s41423-020-00618-z .
Mansilla, M. J., Presas-Rodríguez, S., Teniente-Serra, A., González-Larreategui, I., Quirant-Sánchez, B., Fondelli, F., Nikolovski, Neda, Iwaszkiewicz-Grześ, D., Chwojnicki, K., Miljković, Đorđe, Trzonkowski, P., Ramo-Tello, C., Martínez-Cáceres, E. M., "Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy" in Cellular and Molecular Immunology, 18, no. 6 (2021):1353-1374,
https://doi.org/10.1038/s41423-020-00618-z . .
20
25
5
22